Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0

作者：

Grunwald, Viktor ^{[1
,2
]}

Powles, Thomas ^{[3
,4
]}

Eto, Masatoshi ^{[5
]}

Kopyltsov, Evgeny ^{[6
]}

Rha, Sun Young ^{[7
]}

Porta, Camillo ^{[8
]}

Motzer, Robert ^{[9
]}

Hutson, Thomas E. ^{[10
]}

Mendez-Vidal, Maria Jose ^{[11
]}

Hong, Sung-Hoo ^{[12
]}

Winquist, Eric ^{[13
]}

Goh, Jeffrey C. ^{[14
,15
]}

Maroto, Pablo ^{[16
]}

Buchler, Tomas ^{[17
,18
]}

Takagi, Toshio ^{[19
]}

Burgents, Joseph E. ^{[20
]}

Perini, Rodolfo ^{[21
]}

He, Cixin ^{[22
]}

Okpara, Chinyere E. ^{[23
]}

McKenzie, Jodi ^{[24
]}

Choueiri, Toni K. ^{[25
]}

机构：

[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany

[2] Univ Hosp Essen, Clin Urol, Essen, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] Queen Mary Univ London, Royal Free Hosp, London, England

[5] Kyushu Univ, Dept Urol, Fukuoka, Japan

[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia

[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea

[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Texas Oncol, Med Oncol, Dallas, TX USA

[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain

[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea

[13] Univ Western Ontario, Dept Oncol, London, ON, Canada

[14] ICON Res, South Brisbane, Qld, Australia

[15] Univ Queensland, St Lucia, Qld, Australia

[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic

[18] Thomayer Univ Hosp, Prague, Czech Republic

[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[21] Merck & Co Inc, Clin Res, Rahway, NJ USA

[22] Eisai Inc, Biostat, Nutley, NJ USA

[23] Eisai Ltd, Clin Res, Hatfield, England

[24] Eisai Inc, Clin Res, Nutley, NJ USA

[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 13卷

关键词：

renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;

D O I：

10.3389/fonc.2023.1343027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[21] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
Zhu, Youwen
Liu, Kun
Ding, Dong
Peng, Libo
CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
[22] Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Plimack, Elizabeth R.
Powles, Thomas
Stus, Viktor
Gafanov, Rustem
Nosov, Dmitry
Waddell, Tom
Alekseev, Boris
Pouliot, Frederic
Melichar, Bohuslav
Soulieres, Denis
Borchiellini, Delphine
Mcdermott, Raymond S.
Vynnychenko, Ihor
Chang, Yen-Hwa
Tamada, Satoshi
Atkins, Michael B.
Li, Chenxiang
Perini, Rodolfo
Molife, L. Rhoda
Bedke, Jens
Rini, Brian I.
EUROPEAN UROLOGY, 2023, 84 (05) : 449 - 454
[23] Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
Lee, J. -L.
Ahn, J. -H.
Lim, H. Y.
Park, S. H.
Lee, S. H.
Kim, T. M.
Lee, D. -H.
Cho, Y. M.
Song, C.
Hong, J. H.
Kim, C. -S.
Ahn, H.
ANNALS OF ONCOLOGY, 2012, 23 (08) : 2108 - 2114
[24] Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Atkins, Michael B.
Plimack, Elizabeth R.
Puzanov, Igor
Fishman, Mayer N.
McDermott, David F.
Cho, Daniel C.
Vaishampayan, Ulka
George, Saby
Tarazi, Jamal C.
Duggan, William
Perini, Rodolfo
Thakur, Mahgull
Fernandez, Kathrine C.
Choueiri, Toni K.
EUROPEAN JOURNAL OF CANCER, 2021, 145 : 1 - 10
[25] A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
Voss, Martin H.
Bhatt, Rupal S.
Vogelzang, Nicholas J.
Fishman, Mayer
Alter, Robert S.
Rini, Brian, I
Beck, J. Thaddeus
Joshi, Monika
Hauke, Ralph
Atkins, Michael B.
Burgess, Earle
Logan, Theodore F.
Shaffer, David
Parikh, Rahul
Moazzam, Nauman
Zhang, Xiaosha
Glasser, Chad
Sherman, Matthew L.
Plimack, Elizabeth R.
CANCER, 2019, 125 (14) : 2400 - 2408
[26] Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma
Liu, Yanjie
Meng, Ying
Li, Mengmeng
Dong, Yanjiao
ARCHIVOS ESPANOLES DE UROLOGIA, 2024, 77 (05): : 584 - 590
[27] Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
Agarwal, N.
Brugarolas, J.
Ghatalia, P.
George, S.
Haanen, J. B.
Gurney, H.
Ravilla, R.
van der Veldt, A.
Beuselinck, B.
Pokataev, I.
Suelmann, B. B. M.
Tuthill, M. H.
Vaena, D.
Zagouri, F.
Wu, J.
Perini, R. F.
Liu, Y.
Merchan, J.
Atkins, M. B.
ANNALS OF ONCOLOGY, 2024, 35 (12) : 1148 - 1156
[28] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Satoshi Tamada
Chihiro Kondoh
Nobuaki Matsubara
Ryuichi Mizuno
Go Kimura
Satoshi Anai
Yoshihiko Tomita
Masafumi Oyama
Naoya Masumori
Takahiro Kojima
Hiroaki Matsumoto
Mei Chen
Mengran Li
Kenji Matsuda
Yoshinobu Tanaka
Brian I. Rini
Hirotsugu Uemura
International Journal of Clinical Oncology, 2022, 27 : 154 - 164
[29] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Tamada, Satoshi
Kondoh, Chihiro
Matsubara, Nobuaki
Mizuno, Ryuichi
Kimura, Go
Anai, Satoshi
Tomita, Yoshihiko
Oyama, Masafumi
Masumori, Naoya
Kojima, Takahiro
Matsumoto, Hiroaki
Chen, Mei
Li, Mengran
Matsuda, Kenji
Tanaka, Yoshinobu
Rini, Brian, I
Uemura, Hirotsugu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 154 - 164
[30] A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma
Rini, B.
Redman, B.
Garcia, J. A.
Burris, H. A., III
Li, S.
Fandi, A.
Beck, R.
Jungnelius, U.
Infante, J. R.
ANNALS OF ONCOLOGY, 2014, 25 (09) : 1794 - 1799

← 1 2 3 4 5 →